Sasan Fazeli Edina Paal Jessica H Maxwell Kenneth D Burman Eric S Nylen Shikha G Khosla
10.1177/2324709619890942
J Investig Med High Impact Case Rep
2019 Jan-Dec;7:2324709619890942.
braf v600e braf inhibitor cdk4 mutation ezh2 mutation anaplastic thyroid cancer mitogen-activated extracellular protein kinase inhibitor (mek inhibitor) targeted therapy
CC BY
https://pubmed.ncbi.nlm.nih.gov/31766881/
CDC2 Protein Kinase / genetics Enhancer of Zeste Homolog 2 Protein / genetics Molecular Targeted Therapy Proto-Oncogene Proteins B-raf / genetics Thyroid Carcinoma, Anaplastic / genetics Thyroid Neoplasms / genetics
CDC2 Protein Kinase / genetics Enhancer of Zeste Homolog 2 Protein / genetics Molecular Targeted Therapy Proto-Oncogene Proteins B-raf / genetics Thyroid Carcinoma, Anaplastic / genetics Thyroid Neoplasms / genetics Case Reports Aged Autopsy CDC2 Protein Kinase / antagonists & inhibitors Enhancer of Zeste Homolog 2 Protein / antagonists & inhibitors Fatal Outcome Humans Imidazoles Male Mutation Oximes Positron Emission Tomography Computed Tomography Protein Kinase Inhibitors / therapeutic use Proto-Oncogene Proteins B-raf / antagonists & inhibitors Pyridones Pyrimidinones Thyroid Carcinoma, Anaplastic / drug therapy Thyroid Neoplasms / drug therapy Imidazoles Oximes Protein Kinase Inhibitors Pyridones Pyrimidinones trametinib EZH2 protein, human Enhancer of Zeste Homolog 2 Protein BRAF protein, human Proto-Oncogene Proteins B-raf CDC2 Protein Kinase CDK1 protein, human dabrafenib
PMC6880026
31766881
Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer
2019